- Home
- SMSI vs ATHA Comparison
SMSI vs ATHA Comparison
Compare SMSI & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMSI
- ATHA
- Stock Information
- Founded
- SMSI 1982
- ATHA 2011
- Country
- SMSI United States
- ATHA United States
- Employees
- SMSI N/A
- ATHA N/A
- Industry
- SMSI Computer Software: Prepackaged Software
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- SMSI Technology
- ATHA Health Care
- Exchange
- SMSI Nasdaq
- ATHA Nasdaq
- Market Cap
- SMSI 24.7M
- ATHA 21.0M
- IPO Year
- SMSI 1995
- ATHA 2020
- Fundamental
- Price
- SMSI $0.90
- ATHA $0.26
- Analyst Decision
- SMSI Strong Buy
- ATHA Buy
- Analyst Count
- SMSI 1
- ATHA 4
- Target Price
- SMSI $5.00
- ATHA $11.25
- AVG Volume (30 Days)
- SMSI 144.0K
- ATHA 211.9K
- Earning Date
- SMSI 05-07-2025
- ATHA 05-09-2025
- Dividend Yield
- SMSI N/A
- ATHA N/A
- EPS Growth
- SMSI N/A
- ATHA N/A
- EPS
- SMSI N/A
- ATHA N/A
- Revenue
- SMSI $19,378,000.00
- ATHA N/A
- Revenue This Year
- SMSI $36.40
- ATHA N/A
- Revenue Next Year
- SMSI $46.07
- ATHA N/A
- P/E Ratio
- SMSI N/A
- ATHA N/A
- Revenue Growth
- SMSI N/A
- ATHA N/A
- 52 Week Low
- SMSI $0.52
- ATHA $0.22
- 52 Week High
- SMSI $2.90
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- SMSI 46.04
- ATHA 46.49
- Support Level
- SMSI $0.91
- ATHA $0.23
- Resistance Level
- SMSI $1.09
- ATHA $0.30
- Average True Range (ATR)
- SMSI 0.08
- ATHA 0.03
- MACD
- SMSI -0.01
- ATHA 0.00
- Stochastic Oscillator
- SMSI 1.82
- ATHA 42.87
About SMSI Smith Micro Software Inc.
Smith Micro Software Inc is a provider of software solutions. It develops and markets wireless solutions for wireless service providers, mobile device and chipset manufacturers, and enterprise businesses. It offers multi-platform, modular solutions such as SafePath; CommSuite; and ViewSpot. The company's only reportable segment is Wireless. Its Wireless segment sells to large wireless carriers, cable operators, and OEMs.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.